← Human Trials & Peer-Reviewed Studies
T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly
Plain-language guide to PMID 27649724 (2016): multicenter clinical trial of Octreotide and Somatostatin in 120 patients.
Key Facts
- PMID
- 27649724
- Journal
- Endocrine-related cancer
- Year
- 2016
- Study type
- Clinical Trial
- Authors
- Potorac I et al. (41 authors)
- DOI
- 10.1530/ERC-16-0356
What This Study Did, in Plain Language
What Was Tested
This clinical trial looks at Octreotide and Somatostatin.
GH-secreting pituitary adenomas can be hypo-, iso- or hyper-intense on T2-weighted MRI sequences.
The researchers conducted the current multicenter study in a large population of patients with acromegaly to analyze the relationship between T2-weighted signal intensity on diagnostic MRI and hormonal and tumoral responses to somatostatin analogs (SSA) as primary monotherapy.
Who Took Part
According to the abstract, 120 patients were involved.
The age groups tagged for this paper are middle-aged adults, both men and women.
How the Study Was Run
The design is described as multicenter.
More than one site took part, so the patients came from several places.
What Was Measured
The researchers conducted the current multicenter study in a large population of patients with acromegaly to analyze the relationship between T2-weighted signal intensity on diagnostic MRI and hormonal and tumoral responses to somatostatin analogs (SSA) as primary monotherapy.
Hormonal, clinical and general MRI assessments were performed and assessed centrally.
The subject headings attached to it are Acromegaly, Adenoma, Growth Hormone-Secreting Pituitary Adenoma, Human Growth Hormone, Insulin-Like Growth Factor I, Magnetic Resonance Imaging and Octreotide.
Author keywords: MRI, predictor, somatostatin analogs and treatment response.
What This Means in Plain Language
The paper is a multicenter study of Octreotide and Somatostatin in 120 patients.
The publication is from 2016 (Endocrine-related cancer), a journal based in England.
More context: the Octreotide compound page and the Somatostatin compound page, all human trials.
Our Notes on the Compounds
Octreotide: An 8-amino-acid somatostatin analog (Sandostatin, Mycapssa) used for acromegaly and certain hormone-secreting tumors.
Somatostatin: A 14-amino-acid hormone that switches off the release of several other hormones, including growth hormone and insulin.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.